Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial
about
Cardiac cachexia: hic et nuncStudy Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)Pharmacology of manipulating lean body massCachexia and pancreatic cancer: are there treatment options?Gaps in nutritional research among older adults with cancerMechanisms of metabolic dysfunction in cancer-associated cachexiaSkeletal muscle homeostasis and plasticity in youth and ageing: impact of nutrition and exerciseImportance of Breast Cancer Subtype in the Development of Androgen Receptor Directed Therapy.Are we closer to having drugs to treat muscle wasting disease?Therapies for musculoskeletal disease: can we treat two birds with one stone?Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review.Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signalingEnobosarm (GTx-024, S-22): a potential treatment for cachexia.Sex steroid actions in male boneEstrogens and Androgens in Skeletal Physiology and Pathophysiology.Development of selective androgen receptor modulators (SARMs).Identifying nutritional, functional, and quality of life correlates with male hypogonadism in advanced cancer patientsPHARMACOLOGICAL INTERVENTIONS IN FRAILTY AND SARCOPENIA: REPORT BY THE INTERNATIONAL CONFERENCE ON FRAILTY AND SARCOPENIA RESEARCH TASK FORCE.Unlocking the wasting enigma: Highlights from the 8th Cachexia Conference.Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial).Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies.Androgen effects on skeletal muscle: implications for the development and management of frailty.Selective androgen receptor modulators for the treatment of late onset male hypogonadism.Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options.Integrated therapies for osteoporosis and sarcopenia: from signaling pathways to clinical trials.Targeting the androgen receptor in breast cancer.Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC.Pharmacologic Options for the Treatment of Sarcopenia.The wasting continuum in heart failure: from sarcopenia to cachexia.Advances in pharmacologic strategies for cancer cachexia.Comparative safety evaluation of selective androgen receptor modulators and anabolic androgenic steroids.Cancer-induced muscle wasting: latest findings in prevention and treatment.Bone Pain and Muscle Weakness in Cancer Patients.Rationale for Strengthening Muscle to Prevent Falls and Fractures: A Review of the Evidence.Safety, pharmacokinetics and pharmacological effects of the selective androgen receptor modulator, GSK2881078, in healthy men and postmenopausal women.Mitochondria: Inadvertent targets in chemotherapy-induced skeletal muscle toxicity and wasting?Novel therapeutic options for cachexia and sarcopenia.Evidence for partial pharmaceutical reversal of the cancer anorexia-cachexia syndrome: the case of anamorelin.Update on Management of Cancer-Related Cachexia.
P2860
Q26744140-F91633C0-F014-4606-85E2-C4AE31846C04Q26747940-959E925A-CD38-465F-9196-E9C820DAC1AAQ26824503-AD9F23B7-C164-4794-9E88-903B7EEF73BCQ27026558-9EB4467C-515F-46BD-AED9-D8BE2FF93709Q28067552-E99E2CC4-B9AF-40F9-8920-8F2F4F7B2B3EQ28079213-63C38C75-DF1C-4B6F-9D63-567A4B0E1473Q28262423-AEAE0865-9C5A-486D-A44E-2771283D2958Q33632582-D90D9400-C32D-48EE-AF23-592A60D818C5Q33741103-81562F36-6227-4277-A27B-A66D8B0AB7B2Q33851441-59BCD8D2-8448-45BE-9F99-5283CD37728FQ33956866-F9ADA25D-2CC6-4D4B-882C-1F6CBAE0E4F7Q33966915-B8CB2010-A6B9-4FCC-8651-B65A7D5F5781Q34401825-C7F6CF33-09BD-49F7-BD27-D756F6E5B86BQ34437537-B311F69D-3756-4CBE-8F79-F9CA4C1E901DQ34543980-570E21DC-F905-4865-A636-13AB53FD93AAQ34558010-FC3F3929-F68B-47C5-B43D-F907187F513DQ35981188-69CC95F4-1330-4DA8-A264-00D6C3AC3B97Q36040742-73C51561-2FE2-4912-852B-4D3C2E7AE5A0Q36706618-0530FBA6-FCFE-464B-8C9A-6E4E03B8B96AQ36908403-4E272736-FD67-4CBC-8500-F8D190D5B7F4Q37057905-A395DA31-F625-40AA-B328-6B8E31EAE15BQ37635897-0CB7E64F-DF8E-4E46-A3A0-611CBF41118BQ37639192-DE14772F-A60A-496D-9A98-A04B43876322Q37639204-7854B981-F29D-447B-A7CA-8CAACED0D310Q38290238-153370FA-A755-4122-9D29-279F5FC1C6EEQ38336740-5E9FDF74-E93D-4000-98B3-8A2D3DDF3486Q38349376-2F87E396-C0F7-4BCF-AC23-03B5026F7D18Q38462047-281AFD46-7D57-4AF0-86DD-599CBCF6C620Q38534875-66B3370A-BA0A-45ED-A9D9-8C00C8D1396BQ38564746-AB8F29D9-6B27-4B3A-8D25-6C4B8F5B0A8EQ38578582-F40AB34D-B838-4B60-B793-7EEEDB2CCE8EQ38592105-CD10F8B5-C45E-406B-A8B3-4067C9395A7CQ38681113-55642908-7CDD-4BBC-98BA-ECD4F70126BCQ38684768-C9CA4860-A041-45A0-ADE7-3A40F42F346FQ38723625-C4FDAF4E-839E-4B8C-8B07-5220A462392BQ38816601-E65E2401-6BA1-4515-B97C-54C64F027826Q38831900-C754FBF4-4D4E-4C40-88DD-BCD2D5718E32Q38887581-EBB6481B-694A-4AC1-8D89-7BB57BBD7707Q38931233-56DB879E-233F-4C43-B960-F84CC0318C37Q38990581-784D9B10-1CFD-4836-AE75-1415A72E99D3
P2860
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Effects of enobosarm on muscle ...... mised controlled phase 2 trial
@en
type
label
Effects of enobosarm on muscle ...... mised controlled phase 2 trial
@en
prefLabel
Effects of enobosarm on muscle ...... mised controlled phase 2 trial
@en
P2093
P2860
P1433
P1476
Effects of enobosarm on muscle ...... mised controlled phase 2 trial
@en
P2093
Adrian S Dobs
Christopher C Croot
Mary A Johnston
Michael L Hancock
Mitchell S Steiner
Nashat Y Gabrail
Ralph V Boccia
P2860
P304
P356
10.1016/S1470-2045(13)70055-X
P577
2013-03-14T00:00:00Z